You are here

Article Text

Article menu
Download PDFPDF
Clinical Developments
UK Defence Medical Services Guidance for the Use of Recombinant Factor VIIA (RFVIIA) in the Deployed Military Setting
  1. Colonel TJ Hodgetts, QHP L/RAMC, Honorary Professor of Emergency Medicine1⇓,
  2. E Kirkman2,
  3. PF Mahoney3,
  4. R Russell1,
  5. R Thomas3 and
  6. M Midwinter1
  1. 1Royal Centre for Defence Medicine, Birmingham
  2. 2Defence Science and Technology Laboratories, Porton Down
  3. 3Derriford Hospital, Plymouth
  1. Academic Department of Military Emergency Medicine, Institute of Research & Development, Birmingham Research Park, Vincent Drive, Birmingham, B15 2SQ 0121 415 8844 0121 415 8869 Prof.ADMEM{at}rcdm.bham.ac.uk

Abstract

Use of recombinant Factor VIIa (rFVIIa) for trauma is currently an ‘off label’ use.

There are reports of rFVIIa contributing to the successful outcome of military trauma patients. This paper sets out the current position of the UK Defence Medical Services with regard to using rFVIIa in military trauma.

  • Military Medicine
  • Trauma
  • Haemorrhage
  • Guidelines

https://doi.org/10.1136/jramc-153-04-18

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.